MEDP
Medpace Holdings Inc (MEDP) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...
Article Summary
HOLD- Medpace Holdings Inc. (NASDAQ: MEDP) reported strong revenue growth driven by rising new business awards and strong EBITDA, but continued high cancellation rates in oncology and cardiovascular therapeutic areas.
- Cash flow remained solid, though RFPs declined sequentially and year over year, indicating a potential slowdown in new opportunities.
- Medpace Holdings's backlog reached approximately $2.9 billion as of March 31, 2026, up 2.9% year-over-year, but future revenue growth remains uncertain due to low backlog growth and high cancellations.
- CEO August Troendle said project-specific issues like product performance and re-prioritizations were primarily responsible for the increase in cancellations, with the largest therapeutic areas affected being oncologia and cardiovascular.
- Cash levels remained solid at $652.7 million, supported by steady cash flow and strong cash flow from operations.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 24.2% | 25% | 70.0 ptsGood (24.2%) - Healthy growth |
| EPS Growth Next 5Y ? | 11.2% | 25% | 35.0 ptsBelow Screener (11.2%) - Modest outlook |
| Target Price Upside ? | 18.7% | 20% | 60.0 ptsModerate Upside (18.7%) - Target: $457.45 vs Current: $385.30 |
| Gross Margin % ? | 28.0% | 15% | 40.0 ptsModerate (28.0%) - Adequate margins |
| Drawdown from 52-Wk High ? | -38.7% | 15% | 80.0 ptsSolid Dip (-38.7%) - Good entry zone |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About MEDP
- Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
- The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
- It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
- In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials.
- Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.